Depletion of AHR using small interfering RNAs targeting AHR in pancreatic cancer cells heightens sensitivity to gemcitabine, a chemotherapeutic agent, and diminishes cells’ invasive and migratory potential [171]. Here, AHR is linked to familial pancreatic carcinoma.